Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Infanrix + Havrix
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Infanrix + Havrix refers to the co-administration of GlaxoSmithKline's DTaP vaccine (Infanrix) and its inactivated hepatitis A vaccine (Havrix). Infanrix is a non-infectious sterile vaccine containing diphtheria toxoid, tetanus toxoid, and adsorbed pertussis antigens (pertussis toxoid, filamentous hemagglutinin, and pertactin). Havrix contains a sterile suspension of the HM175 strain of hepatitis A virus that has been inactivated with formaldehyde and adsorbed onto aluminum hydroxide. This combination regimen is used to provide simultaneous active immunization against diphtheria, tetanus, pertussis, and hepatitis A. It is typically evaluated in pediatric populations, such as children around 15 months of age, to simplify vaccination schedules and improve compliance by reducing the number of separate clinic visits required for essential immunizations.
- Brand names
- InfanrixHavrix
- Other names
- Infanrix-GlaxoSmithKline-hepatitis ADTaP + Hepatitis A vaccineHavrix co-administered with Infanrix
02
Targets
FHA (Filamentous hemagglutinin)PRN (Pertactin)HBsAg (Hepatitis B surface antigen)Poliovirus capsid proteinsTT (Tetanus toxoid)
Beyond the preview
Go deeper on Infanrix + Havrix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Infanrix + Havrix.